Boston Scientific shares tick up after Q4 prelims meet estimates | Wall Street Beat

Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street.

The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year.

In Q4, Boston Scientific’s cardiovascular business pulled in $970 million in sales, while its rhythm & neuro unit recorded $790 million in revenue. The company’s MedSurg division saw $800 million in sales, according to an SEC filing.

Most of the company’s Q4 sales were made in the U.S. – $1.46 billion were recorded in the States, with $560 million coming from EMEA, $450 million from APAC and $100 million from Latin America and Canada.

Boston Scientific said it would share full results for Q4 and FY18 on Feb. 6.

BSX shares were trading at $34.96 apiece in morning activity today, up +1.6%.

Hologic tops consensus with Q1 prelims

Hologic (NSDQ:HOLX) said today that it expects to report $831 million in sales for the first quarter of fiscal 2019, up 5% compared to the same time last year.

The number exceeds the company’s previous guidance for the quarter of $800 – $815 million and the consensus on Wall Street. Analysts were looking for Q1 sales of $811.3 million.

Hologic plans to detail its full financial results for Q1 on Jan. 30.

“We expect to post strong first quarter revenue well above our guidance range, driven by acceleration in our largest businesses – U.S. breast health, international, and molecular diagnostics – all of which posted double-digit constant currency growth to start our year,” chairman, president & CEO Steve MacMillan said in prepared remarks.

HOLX shares were trading at $40.95 apiece in morning activity, up +1.1%.

Integra shares climb on promising Q4 prelims

Shares in Integra LifeSciences (NSDQ:IART) rose today after the company said that it expects to report sales for the fourth quarter that land in the higher end of its previous guidance range of $378 – $383 million.

The Plainsboro, N.J.-based company added that organic revenue growth in Q4 is expected to be just above 4%. Integra plans to report its final Q4 and full year 2018 financial results in February.

Analysts have the company’s Q4 and FY18 consensus at $380.8 million and $1.47 billion, respectively.

IART shares were trading at $46,20 apiece in morning activity today, up +3.9%.

SeaSpine Q4, FY18 prelims beat estimates

SeaSpine (NSDQ:SPNE) said today that it expects to report fourth-quarter sales between $37.6 million and $38 million, topping estimates on Wall Street.

The Carlsbad, Calif.-based company pegged its full-year sales for 2018 between $143 million and $143.4 million. As of Dec. 31, the company had $54 million in cash, cash equivalents and investments, according to an SEC filing.

Analysts on Wall Street estimated that SeaSpine will post Q4 sales of $36.3 million and $141.7 million for FY18 sales.

“We are pleased by our strong revenue performance in the fourth quarter, which reflects continued solid growth across our portfolios,” president & CEO Keith Valentine said in prepared remarks. “We are confident that we are well capitalized and positioned to sustain this growth as we continue to deliver cost effective procedural solutions to surgeons and hospitals to improve the quality of patient lives.”

SeaSpine said it expects 2019 revenue to be between $152 – $156 million.

SPNE shares were trading at $17.10 in morning activity, up +1.3%.

The post Boston Scientific shares tick up after Q4 prelims meet estimates | Wall Street Beat appeared first on MassDevice.

from MassDevice http://bit.ly/2C6OSdW